A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

BACKGROUND: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Heart Fail
Main Authors: McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2019
Assuntos:
Trial Designs
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607736/
https://ncbi.nlm.nih.gov/pubmed/30895697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1432
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados